D’Amato et al. demonstrated that a TDO2–AhR signaling axis in a kynurenine pathway promoted anoikis resistance via NF-κB and highlighted that TDO-2 could be an intriguing target for the treatment of triple-negative breast cancer (137). This evidence concerns the gene TDO2 and triple-negative breast carcinoma.